• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

Background High triglyceride levels are associated with increased cardiovascular risk, but
whether reductions in these levels would lower the incidence of cardiovascular events is …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …

Previous interest in high-density lipoproteins (HDLs) focused on their possible protective
role in atherosclerotic cardiovascular disease (ASCVD). Evidence from genetic studies and …

Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

Recent advances in human genetics, together with a large body of epidemiologic,
preclinical, and clinical trial results, provide strong support for a causal association between …

Peroxisome proliferator-activated receptor-α (PPARα), PPARδ and PPARγ are transcription
factors that regulate gene expression following ligand activation. PPARα increases cellular …

Accumulating evidence points to the causal role of triglyceride-rich lipoproteins and their
cholesterol-enriched remnants in atherogenesis. Genetic studies in particular have not only …